Company: ZVRA
Filing Date: 2025-05-08
Form Type: DEFA14A
Source: 0001193125-25-115961
Chunk: 10

Company: ZEVRA THERAPEUTICS, INC.
Filing Date: 2025-05-08
Form: DEFA14A
Chunk 10
---
’s Repeated Efforts to Engage in Good Faith, Mangless Continues to Advance an Unclear Agenda Mangless already has had three nominees elected to the Board in 2023 Mangless' own filings acknowledged that if his two nominees are elected, the five nominees that he will have added to the Board “will constitute a majority on the Board and will potentially be able to implement any actions that they may believe are necessary to unlock stockholder value...” Mangless has detailed no strategies, plans, or new ideas to improve Zevra’s business Mangless’ demands are contradictory in nature In fact, he has expressed agreement with Zevra’s recent actions, including the onboarding of current leadership; yet he still appears focused on replacing two highly-qualified directors with inappropriate nominees He previously shared suggestions about “Increasing the diversity of the Board,” but his nominees would drastically reduce diversity on the Board

Mangless’ Critiques Demonstrate that He Lacks Understanding of Typical Governance Practices at Early-Stage Biotech Companies Majority vote threshold for director elections is not standard industry practice for companies of a similar size, stage, and therapeutic focus Our Board may consider moving to a majority vote threshold as we mature commercially Classified Boards are typical for public biotech companies of similar size, stage, and therapeutic focus Our Board regularly discusses its structure, and our intention is to sunset our classified Board structure at the appropriate time Our Board currently has two women directors, Wendy Dixon, Ph.D. and Tamara Favorito, both of whom are up for re-election this year; Mangless is seeking to replace both Attracting and retaining top-tier talent requires a competitively structured compensation program Compensation Committee and Board evaluated 2024 performance and adjusted executive pay to better align with performance through PSUs Diversity Executive Compensation Classified Board Majority Vote

Vote for the Nominees with the Experience and Expertise to Lead Zevra

Would you rather have: Mangless’ Plan to Add an Unqualified Proxy Solicitor and Former CEO Risks Meaningful Disruption to Zevra Our current five-year strategic plan and upcoming milestones necessitate the right Board to continue execution; we believe that Mr. Mangless’ nominees will put your investment in Zevra at risk Neither of Mr. Mangless’ nominees bring any additive skills or experience to the Board, and we have significant concerns about the potential disruption and distraction to Zevra’s operations that Mr. Mangless’ nominees could bring Risk distraction, disruption, and potential destruction of the Company's value by a single stockholder with un